Purpose of this Study
This study tests a new cancer medicine. It has 3 parts:
- Screening (up to 28 days): You'll get tests like heart checks, scans, and blood work.
- Treatment: You'll visit the clinic every 3 weeks to get the study drug. There are different groups testing the drug with other treatments for cancers like ovarian and endometrial.
- Follow-Up: After treatment, you'll have check-ups at 30, 60, and 90 days, plus long-term follow-up with more tests.
Who Can Participate?
Eligibility
Who can join this study:
- Adults with solid tumors, which are a type of cancer.
- People with advanced or returning endometrial cancer who didn’t get better with regular treatments or can’t use them.
- People whose cancer got worse after at least one kind of treatment.
- People with advanced ovarian, fallopian tube, or peritoneal cancer confirmed by lab tests.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
Doctors are doing a study to test a new cancer medicine called GSK5733584. They want to see if it's safe to use by itself or with other cancer medicines. The goal is to find out if it can help treat solid tumors (a kind of cancer) more effectively.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability,
Pharmacokinetics and Clinical Activity of GSK5733584 in Combination with
Anti-Cancer Agents in Participants with Advanced Solid Tumors
Pharmacokinetics and Clinical Activity of GSK5733584 in Combination with
Anti-Cancer Agents in Participants with Advanced Solid Tumors
Principal Investigator
Angeles
Secord
Protocol Number
PRO00118137
NCT ID
NCT06796907
Phase
I/II
Enrollment Status
Pending Open to Enrollment